720 / 1835
Conclusions – Role of RIT in Follicular lymphoma
•
RIT simple and effective treatment; most active drug in NHL,
unique mechanism of action
–
Effective (high response rate, durable remission) and underused single
treatment in relapsed and rituximab refractory disease
–
Patients in
90
Y-ibritumomab arm had a greater than 5-year advantage in
time to next treatment in FIT trial as consolidation
–
Phase II data as single agents Zevalin RIT in untreated follicular lymphoma
show high response rates and durable remission
–
Novel Radioimmunconjugates are being developed but pathways to
registration and routine clinical use are challenging.